Navidea Biopharmaceuticals Announces 50th Participant Enrolled in the Company's Phase 3 Trial in Rheumatoid Arthritis

Stock Information for Navidea Biopharmaceuticals Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Navidea Biopharmaceuticals Inc.

Navidea Biopharmaceuticals, Inc. Files for Bankruptcy
Navidea Biopharmaceuticals, Inc. Announces Extension of Authority to Implement a Reverse Stock Split
Navidea Biopharmaceuticals Announces the Extension of Plan Designed to Protect NOLs and Other Tax Assets
Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024
Navidea Biopharmaceuticals, Inc. announces special meeting of stockholders to be held July 8, 2024
Navidea Biopharmaceuticals, Inc. Files Form 15 to Voluntarily Deregister and Suspend its SEC Reporting Obligations
Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release
Navidea Biopharmaceuticals, Inc. Announces NYSE American's Decision to Suspend Trading In Its Common Stock

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.